VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

AACR 2021 | Future treatment of relapsed iNHL

Matthew Matasar, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the future treatment of indolent non-Hodgkin lymphoma (iNHL), highlighting the use of copanlisib and rituximab in combination. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Disclosures

Matthew Matasar, MD, has received support and honoraria from Bayer and Roche.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter